Synairgen is an innovative respiratory drug development and commercialisation company. Its primary focus is on developing SNG ... 001 (inhaled interferon beta) for the treatment of hospitalised COVID-19 patients as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. Granted Fast Track status from the US Food and Drug Administration (FDA) and deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR), Synairgen’s Phase III clinical programme is currently evaluating nebulised SNG001 in patients across 17 countries. In a Phase II trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than twofold chance of recovery to ‘no limitation of activities’ versus placebo. Founded by University of Southampton (UK) Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information, please visit www.synairgen.com. read more